Black Diamond Therapeutics vs Coherus Oncology
BDTX and CHRS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BDTX and CHRS compare
Black Diamond Therapeutics and Coherus Oncology are about the same size, with market caps of $92.5M and $90.0M.
Coherus Oncology grew revenue faster over the last twelve months (44.4% versus −100% for Black Diamond Therapeutics).
Black Diamond Therapeutics scores higher on the StockData Score (7 against 6 for Coherus Oncology), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BDTX | CHRS |
|---|---|---|
| Size and price | ||
| Market cap | $92.5M | $90.0M |
| Share price | $1.61 | $0.583 |
| Change, 1 year | −63.1% | −53.8% |
| Change, 5 years | −77.3% | −96.9% |
| Beta (5Y) | 2.49 | 1.39 |
| Employees | 21 | 147 |
| StockData Score | ||
| Total score | 7 (better) | 6 |
| Valuation score | 1 | 2 (better) |
| Growth score | 0 | 2 (better) |
| Performance score | 1 | 1 |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 1.7× |
| P/B | 1.1× (better) | 3.6× |
| Fair value | – | $0.870 |
| Margin of safety | – | 33.1% |
| Growth | ||
| Revenue growth (TTM) | −100% | 44.4% (better) |
| Revenue growth, 5Y average | – | −38.4% |
| Net income growth (TTM) | −305% | −188% (better) |
| EPS growth (TTM) | −311% | – |
| EPS growth, 5Y average | – | −2.5% |
| Profitability | ||
| Gross margin | – | 69.8% |
| Operating margin | – | −276% |
| Net margin | – | −253% |
| Return on equity | −41.1% (better) | −241% |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −15.5× |
| Current ratio | 6.92 (better) | 1.51 |
| Altman Z-score | −4.53 (better) | −14.02 |
| Piotroski F-score | 7 (better) | 6 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 61.0% | 45.5% |
| Held by insiders | 9.1% | 1.3% |
| Short interest, % of float | 9.8% | 8.3% |
Go deeper
- BDTX stock overview
- BDTX income statement
- BDTX valuation and score
- CHRS stock overview
- CHRS income statement
- CHRS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.